A retrospective study of paroxysmal nocturnal hemoglobinuria in pediatric and adolescent patients
|
Mar 2017
|
Blood Cells Mol Dis
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
|
Mar 2015
|
Blood Cancer J
|
myelodysplastic syndromes (MDS)
|
Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes
|
Sep 2017
|
Blood Cancer J
|
myelodysplastic syndromes (MDS)
|
Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation
|
Mar 2012
|
Blood Cancer J
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients
|
Mar 2017
|
Blood Cancer J
|
myelodysplastic syndromes (MDS)
|
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.
|
Feb 2017
|
Blood Cancer J
|
myelodysplastic syndromes (MDS)
|
Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes.
|
Feb 2017
|
Blood Cancer J
|
myelodysplastic syndromes (MDS)
|
Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
|
Apr 2023
|
Blood Cancer
|
myelodysplastic syndromes (MDS)
|
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS
|
Jul 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
Risk and timing of cardiovascular death among patients with myelodysplastic syndromes
|
Oct 2017
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|